SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Westman E) "

Sökning: WFRF:(Westman E)

  • Resultat 31-40 av 340
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
31.
  • Albrecht, F., et al. (författare)
  • Unraveling Parkinson's disease heterogeneity using subtypes based on multimodal data
  • 2022
  • Ingår i: Parkinsonism and Related Disorders. - : Elsevier BV. - 1353-8020 .- 1873-5126. ; 102, s. 19-29
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Parkinson's disease (PD) is a clinically and neuroanatomically heterogeneous neurodegenerative disease characterized by different subtypes. To this date, no studies have used multimodal data that combines clinical, motor, cognitive and neuroimaging assessments to identify these subtypes, which may provide complementary, clinically relevant information. To address this limitation, we subtyped participants with mild-moderate PD based on a rich, multimodal dataset of clinical, cognitive, motor, and neuroimaging variables. Methods: Cross-sectional data from 95 PD participants from our randomized EXPANd (EXercise in PArkinson's disease and Neuroplasticity) controlled trial were included. Participants were subtyped using clinical, motor, and cognitive assessments as well as structural and resting-state MRI data. Subtyping was done by random forest clustering. We extracted information about the subtypes by inspecting their neuroimaging profiles and descriptive statistics. Results: Our multimodal subtyping analysis yielded three PD subtypes: a motor-cognitive subtype characterized by widespread alterations in brain structure and function as well as impairment in motor and cognitive abilities; a cognitive dominant subtype mainly impaired in cognitive function that showed frontoparietal structural and functional changes; and a motor dominant subtype impaired in motor variables without any brain alterations. Motor variables were most important for the subtyping, followed by gray matter volume in the right medial postcentral gyrus. Conclusions: Three distinct PD subtypes were identified in our multimodal dataset. The most important features to subtype PD participants were motor variables in addition to structural MRI in the sensorimotor region. These findings have the potential to improve our understanding of PD heterogeneity, which in turn can lead to personalized interventions and rehabilitation.
  •  
32.
  •  
33.
  •  
34.
  •  
35.
  •  
36.
  • Diaz-Galvan, P., et al. (författare)
  • Differential response to donepezil in MRI subtypes of mild cognitive impairment
  • 2023
  • Ingår i: Alzheimer's Research & Therapy. - 1758-9193. ; 15:1
  • Tidskriftsartikel (refereegranskat)abstract
    • BackgroundDonepezil is an approved therapy for the treatment of Alzheimer's disease (AD). Results across clinical trials have been inconsistent, which may be explained by design-methodological issues, the pathophysiological heterogeneity of AD, and diversity of included study participants. We investigated whether response to donepezil differs in mild cognitive impaired (MCI) individuals demonstrating different magnetic resonance imaging (MRI) subtypes.MethodsFrom the Hippocampus Study double-blind, randomized clinical trial, we included 173 MCI individuals (donepezil = 83; placebo = 90) with structural MRI data, at baseline and at clinical follow-up assessments (6-12-month). Efficacy outcomes were the annualized percentage change (APC) in hippocampal, ventricular, and total grey matter volumes, as well as in the AD cortical thickness signature. Participants were classified into MRI subtypes as typical AD, limbic-predominant, hippocampal-sparing, or minimal atrophy at baseline. We primarily applied a subtyping approach based on continuous scale of two subtyping dimensions. We also used the conventional categorical subtyping approach for comparison.ResultsDonepezil-treated MCI individuals showed slower atrophy rates compared to the placebo group, but only if they belonged to the minimal atrophy or hippocampal-sparing subtypes. Importantly, only the continuous subtyping approach, but not the conventional categorical approach, captured this differential response.ConclusionsOur data suggest that individuals with MCI, with hippocampal-sparing or minimal atrophy subtype, may have improved benefit from donepezil, as compared with MCI individuals with typical or limbic-predominant patterns of atrophy. The newly proposed continuous subtyping approach may have advantages compared to the conventional categorical approach. Future research is warranted to demonstrate the potential of subtype stratification for disease prognosis and response to treatment.
  •  
37.
  •  
38.
  •  
39.
  • Eyjolfsdottir, H., et al. (författare)
  • Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device
  • 2016
  • Ingår i: Alzheimers Research & Therapy. - : Springer Science and Business Media LLC. - 1758-9193. ; 8
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Targeted delivery of nerve growth factor (NGF) has emerged as a potential therapy for Alzheimer's disease (AD) due to its regenerative effects on basal forebrain cholinergic neurons. This hypothesis has been tested in patients with AD using encapsulated cell biodelivery of NGF (NGF-ECB) in a first-in-human study. We report our results from a third-dose cohort of patients receiving second-generation NGF-ECB implants with improved NGF secretion. Methods: Four patients with mild to moderate AD were recruited to participate in an open-label, phase Ib dose escalation study with a 6-month duration. Each patient underwent stereotactic implant surgery with four NGF-ECB implants targeted at the cholinergic basal forebrain. The NGF secretion of the second-generation implants was improved by using the Sleeping Beauty transposon gene expression technology and an improved three-dimensional internal scaffolding, resulting in production of about 10 ng NGF/device/day. Results: All patients underwent successful implant procedures without complications, and all patients completed the study, including implant removal after 6 months. Upon removal, 13 of 16 implants released NGF, 8 implants released NGF at the same rate or higher than before the implant procedure, and 3 implants failed to release detectable amounts of NGF. Of 16 adverse events, none was NGF-, or implant-related. Changes from baseline values of cholinergic markers in cerebrospinal fluid (CSF) correlated with cortical nicotinic receptor expression and Mini Mental State Examination score. Levels of neurofilament light chain (NFL) protein increased in CSF after NGF-ECB implant, while glial fibrillary acidic protein (GFAP) remained stable. Conclusions: The data derived from this patient cohort demonstrate the safety and tolerability of sustained NGF release by a second-generation NGF-ECB implant to the basal forebrain, with uneventful surgical implant and removal of NGF-ECB implants in a new dosing cohort of four patients with AD.
  •  
40.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 31-40 av 340
Typ av publikation
tidskriftsartikel (295)
konferensbidrag (40)
bokkapitel (2)
doktorsavhandling (1)
forskningsöversikt (1)
recension (1)
visa fler...
visa färre...
Typ av innehåll
refereegranskat (282)
övrigt vetenskapligt/konstnärligt (58)
Författare/redaktör
Westman, E (228)
Ferreira, D (82)
Wahlund, LO (72)
Simmons, A. (66)
Lovestone, S (49)
Mecocci, P (46)
visa fler...
Soininen, H (44)
Westman, M (42)
Tsolaki, M (41)
Vellas, B (40)
Kloszewska, I (35)
Muehlboeck, JS (31)
Spenger, C (29)
Aarsland, D (26)
Melen, E (25)
Kull, I (25)
Cavallin, L (21)
Granberg, T (21)
Wickman, M (19)
Bergstrom, A (18)
Poulakis, K (16)
Westman, J (15)
Wahlund, L. O. (15)
Pereira, JB (15)
Skoog, Ingmar, 1954 (13)
Eriksdotter, M (13)
Shams, S. (13)
Hillert, J (12)
Kern, Silke (11)
Asarnoj, A (11)
Beyer, MK (10)
Winblad, B (10)
Nordberg, A (10)
Piehl, F (10)
Heinz, A (10)
Jack, CR (10)
Paus, T (10)
Pausova, Z (10)
Zettergren, Anna, 19 ... (10)
Blennow, Kaj, 1958 (9)
Oppedal, K (9)
Olsson, T (9)
Kockum, I. (9)
Hort, J (9)
Bousquet, J (9)
Schumann, G (9)
Aguilar, C (9)
Hansson, O. (9)
Ekman, U (9)
Ballardini, N (9)
visa färre...
Lärosäte
Karolinska Institutet (287)
Göteborgs universitet (36)
Uppsala universitet (35)
Lunds universitet (30)
Umeå universitet (15)
Karlstads universitet (7)
visa fler...
Stockholms universitet (5)
Kungliga Tekniska Högskolan (3)
Örebro universitet (3)
Linköpings universitet (3)
Chalmers tekniska högskola (3)
Högskolan Kristianstad (1)
Luleå tekniska universitet (1)
Marie Cederschiöld högskola (1)
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (338)
Svenska (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (82)
Samhällsvetenskap (9)
Naturvetenskap (8)
Teknik (3)
Lantbruksvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy